Publications

Please contact us for further information about any of the key publications:

BARD1

1. Irminger-Finger I, JV Soriano, G Vaudan, R Montesano, and AP Sappino (1998). In vitro repression of BARD1 (Brca1-associated RING domain gene) induces phenotypic changes in mammary gland epithelial cells. J Cell Biol 143, 1329-1339. IF 13.955
2. Soriano J, I Irminger-Finger, H Uyttendaele, G Vaudan, J Kitajewsky, AP Sappino, and R Montesano (2000). Repression of putative tumor suppressor gene BARD1 or expression of Notch4(int-3) oncogene subvert the morphogenetic properties of mammary epithelial cells. Adv Exp Med Biol 480, 175-184.
3. Gautier F, I Irminger-Finger, M Grégoire, K Meflah, and J Harp (2000). Identification of an apoptotic cleavage product of BARD1 as autoantigen: a potential key factor in anti-tumoral response. Cancer Research 60, 6895-6900. IF 8.5
4. Irminger-Finger I, WC Leung, J Li, M Dubois-Dauphin, J Harb, A Feki, CE Jefford, JV Soriano, M Jaconi, R Montesano, and KH Krause (2001). Identification of BARD1 as mediator between proapoptotic stress and p53-dependent apoptosis. Mol Cell 8, 1255-1266. IF 18.195
5. Irminger-Finger I, and WC Leung (2002). BRCA1-dependent and independent functions of BARD1. Int J Biochem Cell Biol 34, 582-587. IF 4.904
6. Jefford, CE, A Feki, J Harb, KH Krause, and I Irminger-Finger (2004). Nuclear cytoplasmic translocation of BARD1 is linked to its apoptotic activity. Oncogene 23(20):3509-20. IF 6.8
7. Feki A, CE Jefford, P Durand, J Harb, H Lukas, KH Krause, and I Irminger-Finger (2004). BARD1 Expression during Spermatogenesis is Associated with Apoptosis and Hormonally Regulated. Biol Reprod 71(5):1614-24. IF 3.65
8. Feki A, CE Jefford, P Berardi, JY Wu, L Cartier, KH Krause, and I Irminger-Finger (2005). BARD1 induces apoptosis by catalyzing phosphorylation of p53 by DNA-damage response kinase. Oncogene 24, 3726-3736. IF 6.8
9. Irminger-Finger I, S Busquets, F Calabrio, FJ López-Soriano, and JM Argilés (2006). BARD1 content correlates with increased DNA fragmentation associated with muscle wasting in tumour-bearing rats. Oncolgy Reports 15(6):1425-8. IF 2.792
10. Wu JY, AT Vlastos, MF Pelte, MA Caligo, A Bianco, KH Krause, GJ Laurent, and I Irminger-Finger (2006). Aberrant expression of BARD1 is associated with poor prognosis in breast and ovarian cancers. Int J Cancer 118, 1215-26. IF 4.90
11. Irminger-Finger I and CE Jefford (2006). Is there more to BARD1 than BRCA1? Invited review for Nature Reviews Cancer 6(5):382-91. IF 588
12. Li L, M Cohen, JY Wu, MH Sow, B Nikolic, P Bischof, and I Irminger-Finger (2007). Identification of splice-isoforms of BARD1 involved in human trophoblast invasion. Int J Biochem Cell Biol 39(9):1659-1672. IF 4.804
13. Li L, S Ryser, E Dizin, D Pils, M Krainer, CE Jefford, F Bertoni, R Zeillinger, and I Irminger-Finger (2007). Oncogenic BARD1 isoforms expressed in gynecological cancers. Cancer Research 67(24):11876-85. IF 7.820
14. Ryser S, E Dizin, CE Jefford, B Delaval, A Christodoulidou, S Gagos, KH Krause, D Birnbaum, and I Irminger-Finger (2009). Distinct roles of BARD1 isoforms in mitosis: full length BARD1 mediates Aurora B degradation, cancer-associated BARD1β scaffolds Aurora B and BRCA2. Cancer Research 69(3):1125-34. IF 7.820
15. Irminger-Finger I (2009). BARD1 a possible biomarker candidate for breast and ovarian cancer. Gynecologic Oncology, 2010 May;117(2):211-5. IF 2.919
16. Dizin E and I Irminger-Finger (2010). Regulatory feedback loop between ERα and the BRCA1-BARD1 ubiquitin ligase antagonized by target binding BARD1 mutants in cancer. Int J Biochem Cell Biol 42(5):693-700. IF 4.9
17. Irminger-Finger I, Thomson JM, Kim JK (2010). MicroRNAs, a superimposed regulatory network important for development and disease. Int J Biochem Cell Biol. 42(8):1234-5. IF 4.904
18. Zhang YQ, A Bianco, A M Malkinson, V P Leoni, G Frau, N De Rosa, PA André, R Versace, M Boulvain, G J Laurent, L Atzori, I Irminger-Finger (2011). BARD1: an independent predictor of survival in non-small cell lung cancer. Int J Cancer. Aug 3..
19. Irminger-Finger I (2011). BARD1. Molecule page in Nature Signalling Gateway.
20. Bosse KR, Diskin SJ, Cole KA, Wood AC, Schnepp RW, Norris G, Nguyen LB, Jagannathan J, Laquaglia M, Winter C, Diamond M, Hou C, Attiyeh EF, Mosse YP, Pineros V, Dizin E, Zhang Y, Asgharzadeh S, Seeger RC, Capasso M, Pawel BR, Devoto M, Hakonarson H, Rapport EF, Irminger-Finger I, Maris JM. Common Variation at BARD1 Results in the Expression of an Oncogenic Isoform that Influences Neuroblastoma Susceptibility and Oncogenicity. Cancer Res. 2012 Apr 15;72(8):2068-78. IF 8.2
21. Zhang YQ, Pilyugin M, Kuester M, Leoni VP, Li L, Casula G, Zorcolo Z, Schneider-Stock R, Atzori L, and Irminger-Finger I. Expression of oncogenic BARD1 isoforms affects colon cancer progression and correlates with clinical outcome. British J Cancer 2012 Aug 7;107(4):675-83. IF 4.83
22. Lepore I, Dell’Aversana D, Pilyugin M, Conte M, Nebbioso A, De Bellis F, Tambaro FP, Izzo T, Garcia-Manero G, Ferrara F, Irminger-Finger I, and Altucci I. HDAC inhibitors repress BARD1 isoform expression in acute myeloid leukemia cells via activation of miR-19a and/or b. PlosONE 2013, 8(12): e83018. IF 4.1
23. Pilyugin M, Irminger-Finger. Long non-coding RNA and microRNAs might act in regulating the expression of BARD1 mRNAs. Int J Biochem Cell Biol. 2014 Sep;54:356-67.
24. Irminger-Finger I, Kargul J, Laurent GJ. Rare cancers: What we can learn from them. Int J Biochem Cell Biol. 2014 Aug;53:459-60.
25. Irminger-Finger I, Kargul J, Laurent GJ. Non-coding RNAs: a novel level of genome complexity. Int J Biochem Cell Biol. 2014 Sep;54:286.
26. Nowakowska B, et al. & Irminger-Finger I, Limon J, and Kozlow P. Analysis of large mutations in BARD1 in patients with breast and/or ovarian cancer: the Polish population as an example. Sci Rep. 2015 May 21; 5: 10424..
27. Ratajska M, Matusiak M, Kuzniacka A, Wasag B, Brozek I, Biernat W, Koczkowska M, Debniak J, Sniadecki M, Kozlowski P, Klonowska K, Pilyugin M, Wydra D, Laurent G, Limon J, Irminger-Finger Cancer predisposing BARD1 mutations affect exon skipping and are associated with overexpression of specific BARD1 isoforms. Oncol Rep. 2015 Nov;34(5):2609-17.
28. André PA, Prêle CM, Vierkotten S, Carnesecchi S, Donati Y, Chambers RC, Pache JC, Crestani B, Barazzone-Argiroffo C, Königshoff M, Laurent GJ, Irminger-Finger BARD1 mediates TGF-β signaling in pulmonary fibrosis. Respir Res. 2015 Sep 29;16:118.
29. Irminger-Finger I, Ratajska M, Pilyugin M. New concepts on BARD1: Regulator of BRCA pathways and beyond. Int J Biochem Cell Biol. 2016 Mar; 72:1-17.
30. Marzec KA, Martino-Echarri E, Irminger-Finger I, Henderson BR. BARD1 splice variants display mislocalization in breast cancer cells and can alter the apoptotic response to cisplatin. Cancer Lett. 2016 Jul 28;381(1):149-155.
31. Pilyugin M, Descloux P, André P-A, Laszlo V, Dome B, Hegedus B, Sardy S, Janes S, Bianco A, Laurent G, Irminger-Finger. (2017) BARD1 serum autoantibodies for early detection of lung cancer. PLoS ONE 12(8): e0182356. https://doi.org/10.1371/journal.pone.0182356 
32. Pilyugin M, Ratasjka M, Stukan M, Concin N, Zeillinger R, Irminger-Finger I. BARD1 Autoantibody Blood Test for Early Detection of Ovarian Cancer. Genes. 2021; 12(7): 969. https://doi.org/10.3390/genes12070969

hTERT

1. Allison DB, Sharma R, Cowan ML, VandenBussche CJ: Evaluation of Sienna Cancer Diagnostics hTERT antibody on 500 consecutive urinary tract specimens. Acta Cytologica 2018, DOI: 10.1159/000489181.
2. Lalla M, VandenBussche CJ, Huan G, Anderson P: The hTERT ICC Test as an Adjunct to Urine Cytology: A Longitudinal Follow-Up. Poster presented at ICC 2020: 22nd International Conference on Cytology London, United Kingdom during May 21-22, 2020.

NETs

1. To be updated

SubB2M

1. Day CJ, Paton AW, Higgins MA, Shewell LK, Jen FE-C, Schulz BL, Herdman BP, Paton JC, Jennings MP (2017). Structure aided design of a Neu5Gc specific lectin. Nature Scientific Reports; 7: 1495
2. Wang J, Shewell LK, Paton AW, Paton JC, Day CJ, Jennings MP (2018). Specificity and utility of SubB2M, a new N-glycolylneuraminic acid lectin. Biochemical and Biophysical Research Communications 500: 765-771
3. Shewell LK, Wang JJ, Paton JC, Paton AW, Day CJ, Jennings MP (2018). Detection of N-glycolylneuraminic acid biomarkers in sera from patients with ovarian cancer using an engineered N-glycolylneuraminic acid-specific lectin SubB2M. Biochemical and Biophysical Research Communications 507: 173-177. https://doi.org/10.1016/j.bbrc.2018.11.001
4. Shewell LK, Day CJ, Kutasovic JR, Abrrahams JL, Wang J, Poole J, Niland C, Ferguson K, Saunus JM, Lakhani SR, von Itzstein M, Paton JC, Paton AW, Jennings MP. N-glycolylneuraminic acid serum biomarker levels are elevated in breast cancer patients at all stages of disease. bioRxiv (preprint Aug 2021). doi: https://www.biorxiv.org/content/10.1101/2021.06.21.449179v2 
5. Lucy K. Shewell, Christopher J. Day, Jamie R. Kutasovic, Jodie L. Abrahams, Jing Wang, Jessica Poole, Colleen Niland, Kaltin Ferguson, Jodi M. Saunus, Sunil R. Lakhani, Mark von Itzstein, James C. Paton, Adrienne W. Paton and Michael P. Jennings. https://rdcu.be/cJ21m